Drug maker Cumberland Pharmaceuticals (CPIX) is falling after Wells Fargo analyst Michael Tong downgraded the stock to Market Perform from Outperform in a note to investors earlier this morning. Another pharmaceutical company, Innopharma, has received FDA approval to market a generic version of Cumberland's Acetadopte, a treatment for chronic pulmonary disease and acute bronchopulmonary disease, the analyst wrote. Tong doesn't know when Innopharma will begin marketing its drug, and he believes that Cumberland may seek a preliminary injunction that could postpone the launch. Still, the analyst believes that Cumebrland's stock is unlikely to appreciate as long as uncertainty about the matter persists. In mid-morning trading, Cumberland fell 27c, or 4.88%, to $5.22.